PEP, PrEP and Paparazzis: 2026 HIV Update
Tracking # 20-1373621
$99999.00
There are no ratings for this course
Learn more Educator AMERICAN PHARMACISTS ASSOCIATION
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
0202-0000-26-220-H02-P This course will provide an overview of the most recent developments in HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in a flash! Content will include updates to CDC guidelines, recent clinical data, and the FDA's approval of lenacapavir (Yeztugo) in June 2025 as a twice-yearly option for PrEP. Participants will review current prevention regimens, emerging therapies, and key considerations for optimizing patient access, adherence, and outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
1h
General